Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent CLNN Stock Price: $1.81
Summary: Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.
Sumant Kulkarni analyst at Canaccord Genuity reiterates coverage on Clene (CLNN) stock in the energy sector with a Buy rating and has set CLNN's stock price target at $ 6.
TipRanks.com reports that Clene currently has 4 analysts offering 12-month price targets on CLNN and the consensus is a Strong Buy rating with an average stock price target of $8.67. The most recent CLNN stock price we have is $1.81 and we are not making any CLNN forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for CLNN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CLNN. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CLNN, please click here >>
Alnylam Pharma, ALNY
Recent ALNY Stock Price: $201.02
Summary: Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
Maury Raycroft analyst at Jefferies reiterates coverage on Alnylam Pharma (ALNY) stock in the energy sector with a Buy rating and has set ALNY's stock price target at $ 232.
TipRanks.com reports that Alnylam Pharma currently has 20 analysts offering 12-month price targets on ALNY and the consensus is a Moderate Buy rating with an average stock price target of $236.68. The most recent ALNY stock price we have is $201.02 and we are not making any ALNY forecasts at this time.
In addition, TradingView issued a Neutral rating for ALNY over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALNY. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALNY, please click here >>
Prometheus Biosciences, RXDX
Recent RXDX Stock Price: $59.48
Summary: Prometheus Biosciences Inc. is a biotechnology company. It involved in the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease. Prometheus Biosciences Inc. is based in SAN DIEGO.
Gregory Renza analyst at RBC Capital reiterates coverage on Prometheus Biosciences (RXDX) stock in the energy sector with a Buy rating and has set RXDX's stock price target at $ 66.
TipRanks.com reports that Prometheus Biosciences currently has 9 analysts offering 12-month price targets on RXDX and the consensus is a Strong Buy rating with an average stock price target of $64.00. The most recent RXDX stock price we have is $59.48 and we are not making any RXDX forecasts at this time.
In addition, TradingView issued a Buy rating for RXDX over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RXDX. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RXDX, please click here >>
Intercept Pharma, ICPT
Recent ICPT Stock Price: $14.06
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
Geoff Meacham analyst at Bank of America Securities reiterates coverage on Intercept Pharma (ICPT) stock in the energy sector with a Sell rating and has set ICPT's stock price target at $ 14.
TipRanks.com reports that Intercept Pharma currently has 11 analysts offering 12-month price targets on ICPT and the consensus is a Moderate Buy rating with an average stock price target of $24.00. The most recent ICPT stock price we have is $14.06 and we are not making any ICPT forecasts at this time.
In addition, TradingView issued a Sell rating for ICPT over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ICPT, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================